ADMA Biologics Inc (ADMA)
6.54
+0.34
(+5.48%)
USD |
NASDAQ |
Apr 23, 16:00
6.535
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Net Income (Quarterly): -17.64M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.64M |
| September 30, 2023 | 2.565M |
| June 30, 2023 | -6.371M |
| March 31, 2023 | -6.789M |
| December 31, 2022 | -12.23M |
| September 30, 2022 | -14.90M |
| June 30, 2022 | -13.76M |
| March 31, 2022 | -25.01M |
| December 31, 2021 | -16.65M |
| September 30, 2021 | -17.71M |
| June 30, 2021 | -18.91M |
| March 31, 2021 | -18.38M |
| December 31, 2020 | -19.41M |
| September 30, 2020 | -16.92M |
| June 30, 2020 | -20.18M |
| March 31, 2020 | -19.25M |
| December 31, 2019 | -10.56M |
| September 30, 2019 | -11.44M |
| June 30, 2019 | -13.21M |
| March 31, 2019 | -13.07M |
| December 31, 2018 | -18.04M |
| September 30, 2018 | -15.14M |
| June 30, 2018 | -14.75M |
| March 31, 2018 | -17.82M |
| December 31, 2017 | -12.98M |
| Date | Value |
|---|---|
| September 30, 2017 | -15.20M |
| June 30, 2017 | -9.036M |
| March 31, 2017 | -6.537M |
| December 31, 2016 | -4.559M |
| September 30, 2016 | -4.331M |
| June 30, 2016 | -6.012M |
| March 31, 2016 | -4.612M |
| December 31, 2015 | -4.583M |
| September 30, 2015 | -5.102M |
| June 30, 2015 | -4.679M |
| March 31, 2015 | -3.606M |
| December 31, 2014 | -3.563M |
| September 30, 2014 | -3.385M |
| June 30, 2014 | -3.961M |
| March 31, 2014 | -5.904M |
| December 31, 2013 | -4.701M |
| September 30, 2013 | -2.689M |
| June 30, 2013 | -4.895M |
| March 31, 2013 | -3.242M |
| December 31, 2012 | -2.252M |
| September 30, 2012 | -3.246M |
| June 30, 2012 | -1.207M |
| March 31, 2012 | -0.5973M |
| December 31, 2011 | -0.0083M |
| September 30, 2011 | -0.0052M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-25.01M
Minimum
Mar 2022
2.565M
Maximum
Sep 2023
-14.57M
Average
-16.65M
Median
Dec 2021
Net Income (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | -2.40M |
| ANI Pharmaceuticals Inc | 1.155M |
| Ligand Pharmaceuticals Inc | 18.19M |
| Puma Biotechnology Inc | 12.27M |
| Bristol-Myers Squibb Co | 1.762B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 73.90M |
| Total Expenses (Quarterly) | 59.67M |
| EPS Diluted (Quarterly) | -0.08 |
| Enterprise Value | 1.572B |
| Gross Profit Margin (Quarterly) | 42.06% |
| Profit Margin (Quarterly) | -23.88% |
| Earnings Yield | -1.99% |
| Operating Earnings Yield | 1.48% |
| Normalized Earnings Yield | -0.2168 |